Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma
Status:
Recruiting
Trial end date:
2023-06-20
Target enrollment:
Participant gender:
Summary
This study is designed as Phase II/III. Phase II is aimed to evaluate safety and efficacy of
Simmtecan and the 5-FU/LV regimen (FOLFSIM regimen) plus Toripalimab. Phase III is aimed to
verify inferiority of the overall survival of FOLFSIM regimen plus Toripalimab in comparison
with EP/EC in advanced or metastatic neuroendocrine cancer.